Breast Cancer | Specialty

Dr. Rugo Discusses Late Recurrence in HR+ Breast Cancer

October 31st 2017

Hope Rugo, MD, professor of medicine, director of the Breast Oncology Clinical Trials Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses late recurrence in patients with hormone receptor (HR)-positive breast cancer.

Dr. Yardley Discusses CDK4/6 Inhibitors for Breast Cancer

October 30th 2017

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses CDK4/6 inhibitors for patients with breast cancer.

Dr. van 't Veer on Guidelines for Genetic Testing in Breast Cancer

October 27th 2017

Laura van ’t Veer, PhD, Leader of the Breast Oncology Program, and director of Applied Genomics, UCSF Helen Diller Family Comprehensive Cancer Center, discusses the guidelines for genetic testing in breast cancer.

CDK4/6 Inhibitors Revolutionize Hormone-Positive Breast Cancer Care

October 27th 2017

Denise A. Yardley, MD, discusses the promise of CDK4/6 inhibitors in estrogen receptor–positive breast cancer, and the potential with immunotherapy agents.

Dr. O'Regan on Biomarker Research in Breast Cancer

October 27th 2017

Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses biomarker research in breast cancer.

Individualized Adjuvant Endocrine Approach Appropriate in Breast Cancer

October 25th 2017

Ten-year results from the TEAM trial on exemestane alone and sequential treatment with tamoxifen followed by exemestane for postmenopausal women with hormone receptor-positive breast cancer showed they were reasonable treatment options.

Neratinib Offers Hope in Treatment of CNS Metastases in HER2+ Breast Cancer

October 25th 2017

Rachel A. Freedman, MD, discusses treating patients with HER2-positive breast cancer who develop CNS metastases, and the promise that neratinib holds in this patient population.

Hamilton Highlights Progress in HER2-Positive Breast Cancer

October 25th 2017

Erika P. Hamilton, MD, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Dr. Hamilton Discusses Tucatinib in HER2+ Breast Cancer

October 24th 2017

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses tucatinib in the treatment of patients with HER2-positive breast cancer.

Dr. Burris on the Potential of PARP Inhibitors in TNBC

October 24th 2017

Howard “Skip” A. Burris, III, MD, chief medical officer, Sarah Cannon Research Institute, and a 2014 Giant of Cancer Care® in Drug Development, discusses the potential of PARP inhibitors in patients with triple negative breast cancer (TNBC).

FDA Grants Olaparib Priority Review in BRCA+ Breast Cancer

October 18th 2017

The FDA has granted a priority review to a supplemental New Drug Application for olaparib (Lynparza) for the treatment of patients with germline BRCA-positive, HER2-negative metastatic breast cancer.

Dr. Gradishar Discusses Dual HER2-Targeting in Breast Cancer

October 18th 2017

William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses dual HER2-targeting in breast cancer.

Dr. Hamilton on Extended Adjuvant Therapy for HER2+ Breast Cancer

October 16th 2017

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the role of extended adjuvant therapy for patients with HER2-positive breast cancer.

Dr. Gradishar on the Role of Neratinib in the Treatment of HER2+ Breast Cancer

October 13th 2017

William J. Gradishar, MD, interim chief of Hematology and Oncology in the Department of Medicine, Betsy Bramsen Professorship of Breast Oncology, professor of Medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses the role of neratinib (Nerlynx) in the treatment of patients with HER2-positive breast cancer.

FDA Grants Priority Review to Frontline Abemaciclib for HR+/HER2- Advanced Breast Cancer

October 12th 2017

The FDA has granted a priority review to a new drug application for abemaciclib for use in combination with an aromatase inhibitor for the frontline treatment of women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer.

Dr. Muss on Determining Treatments for HER2+ Breast Cancer

October 10th 2017

Hyman B. Muss, MD, professor of medicine, University of North Carolina-Chapel Hill School of Medicine, Breast Cancer Geriatric Oncology Program, director, geriatric oncology, UNC Lineberger Comprehensive Cancer Center, 2017 Giant of Cancer Care in Supportive/Palliative/Geriatric Care, discusses determining treatments for patients with HER2-positive breast cancer.

Dr. Hamilton on How Neratinib Targets HER2+ Breast Cancer

October 8th 2017

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses how neratinib (Nerlynx) targets HER2-positive breast cancer.

The Path Forward in Breast Cancer Research

October 5th 2017

AR-Targeted Therapy and Immunotherapy for TNBC

October 5th 2017

Role of Neoadjuvant Platinum-Based Therapy for TNBC

October 5th 2017